Skip to main content
. 2021 Nov 11;83(1):16–54. doi: 10.1002/ddr.21895

FIGURE 3.

FIGURE 3

The distribution of different categories of small molecules in COVID‐19 clinical trials as of April 22, 2021. Sub‐classes are made based on the clinical features of COVID‐19 and their possible MOAs